Valneva obtains positive results in Phase 2 for the chikungunya vaccine in children

Valneva announced positive final Phase 2 results regarding the safety and antibody persistence of its chikungunya vaccine, IXCHIQ®, in children. The study, conducted with 304 children, demonstrated that the vaccine is well tolerated, regardless of dose or prior infection.

Twelve months after vaccination, antibody levels remain high, particularly with a full dose. These results support the decision to proceed to a Phase 3 trial. The trial was supported by the Coalition for Epidemic Preparedness Innovations and the European Union. Valneva plans to launch a future Phase 3 pediatric study.

Brazil and India report the majority of cases, highlighting the importance of globally accessible vaccination. Valneva, in partnership with regulatory authorities, continues its efforts to make the vaccine available to all age groups, especially in low-income countries.